DelveInsight’s, “Muscle spasticity – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Muscle spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Muscle spasticity Understanding
Muscle spasticity: Overview
When the muscles contract, become stiff, or spasm involuntarily, it’s called spasticity. Spasticity occurs when the nerve impulses that control muscle movement are interrupted or damaged. Signs and symptoms may include: muscle tightness, joint stiffness, muscle spasms, back pain, abnormal positioning of fingers, wrists, arms, or shoulders and others. The main cause of spasticity is damage to the nerve pathways that control muscle movement. If spasticity is not properly managed, it can result in frozen joints and pressure sores on the skin. Treatment is based on the frequency and level of spasticity, and the underlying condition that’s causing it.

"Muscle spasticity - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle spasticity pipeline landscape is provided which includes the disease overview and Muscle spasticity treatment guidelines. The assessment part of the report embraces, in depth Muscle spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
● The companies and academics are working to assess challenges and seek opportunities that could influence Muscle spasticity R&D. The therapies under development are focused on novel approaches to treat/improve Muscle spasticity.

Muscle spasticity Emerging Drugs Chapters
This segment of the Muscle spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Muscle spasticity Emerging Drugs
● Arbaclofen ER: Osmotica Pharmaceuticals
Arbaclofen ER is an extended release formulation of arbaclofen, the R isomer of baclofen, that leverages proprietary Osmodex drug delivery system and is being studied for the treatment of muscle spasticity resulting from multiple sclerosis. Osmotica Pharmaceuticals has submitted an amended NDA to the US FDA for spasticity in patients with Multiple sclerosis.

● IPN-10200: Ipsen
IPN-01200 is a Neuromuscular blocking agent in development for the treatment of muscle spasticity. Ipsen plans a phase I/II LANTIMA trial for muscle Spasticity in March 2021.
Further product details are provided in the report……..

Muscle spasticity: Therapeutic Assessment
This segment of the report provides insights about the different Muscle spasticity drugs segregated based on following parameters that define the scope of the report, such as:
● Major Players in Muscle spasticity
There are approx. 5+ key companies which are developing the therapies for Muscle spasticity. The companies which have their Muscle spasticity drug candidates in the most advanced stage, i.e. phase III include, Osmotica Pharmaceuticals.
● Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration
Muscle spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular
● Molecule Type

Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
● Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Muscle spasticity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscle spasticity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscle spasticity drugs.

Muscle spasticity Report Insights
• Muscle spasticity Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Muscle spasticity Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Muscle spasticity drugs?
• How many Muscle spasticity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscle spasticity?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscle spasticity therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Muscle spasticity and their status?
• What are the key designations that have been granted to the emerging drugs?